We are live on
!
Find out more
TA
Tamarack Advisers Portfolio holdings
AUM
$2.12M
1-Year Est. Return
58.09%
This Fund
S&P 500
This Quarter
Est. Return
+12.23%
1 Year Est. Return
-58.09%
3 Year Est. Return
-46.51%
5 Year Est. Return
+44.44%
10 Year Est. Return
–
AUM
$299M
AUM Growth
+$88.5M
(+42%)
Cap. Flow
+$68.9M
Cap. Flow
% of AUM
23.07%
Top 10 Holdings %
Top 10 Hldgs %
67.92%
Holding
32
New
5
Increased
19
Reduced
3
Closed
4
Top Buys
| 1 |
OPTN
OptiNose
OPTN
|
+$12.2M |
| 2 |
Medtronic
MDT
|
+$11.2M |
| 3 |
Labcorp
LH
|
+$9.84M |
| 4 |
Rigel Pharmaceuticals
RIGL
|
+$9.34M |
| 5 |
Lantheus
LNTH
|
+$8.76M |
Top Sells
| 1 |
QuidelOrtho
QDEL
|
+$8.55M |
| 2 |
Alkermes
ALKS
|
+$6.38M |
| 3 |
Steris
STE
|
+$4.2M |
| 4 |
CERN
Cerner Corp
CERN
|
+$2.61M |
| 5 |
VSI
Vitamin Shoppe Inc.
VSI
|
+$1.06M |
Sector Composition
| 1 | Healthcare | 89.45% |
| 2 | Industrials | 5.46% |
| 3 | Consumer Discretionary | 2.32% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$775B
| $936K | 0.31% |
+6,000
| New | +$1.62M |
|
|
PDCO
27
PUT
DELISTED
Patterson Companies, Inc.
PDCO
| $469K | 0.16% |
+1,630
| New | +$36.7K |
|
28
PUT
Henry Schein
HSIC
$9.99B
| $425K | 0.14% |
+1,275
| New | +$71.9K |
|
|
29
Alkermes
ALKS
$8.72B
| – | – |
-110,000
| Closed | -$6.38M |
|
|
30
QuidelOrtho
QDEL
$1.2B
| – | – |
-165,000
| Closed | -$8.55M |
|
|
31
Steris
STE
$21.2B
| – | – |
-45,000
| Closed | -$4.2M |
|
|
CERN
32
DELISTED
Cerner Corp
CERN
| – | – |
-45,000
| Closed | -$2.61M |
|
Similar funds
SCM
LBC
ICM
LCMP
GIP
STC
GC
DU
Tamarack Advisers's Q2 2018 Portfolio in Review
As of Q2 2018, Tamarack Advisers held 32 positions worth $299M, up 42% from $210M the previous quarter. Its ten largest holdings account for 68% of the portfolio.
Tamarack Advisers deployed $68.9M of net new capital in Q2 2018, opening 5 new positions and adding to 19 existing holdings. Its largest new stake was Rigel Pharmaceuticals: 262,500 shares worth $7.43M.
By sector, the portfolio is most concentrated in Healthcare at 89% of assets, up from 89% a quarter earlier, followed by Industrials and Consumer Discretionary.
On the sell side, the largest reduction was Vitamin Shoppe Inc., an estimated $1.06M trimmed.
- Tamarack Advisers's largest Q2 2018 buy was Rigel Pharmaceuticals: 262,500 shares worth $7.43M.
- Tamarack Advisers added most to OptiNose in Q2 2018, an estimated $12.2M increase.
- Tamarack Advisers's biggest Q2 2018 reduction was Vitamin Shoppe Inc., cutting an estimated $1.06M.
- Tamarack Advisers fully exited QuidelOrtho in Q2 2018, selling an estimated $8.55M.
- Tamarack Advisers's ten largest holdings make up 68% of its $299M portfolio in Q2 2018.
- Tamarack Advisers opened 5 new positions and closed 4 in Q2 2018.
- Tamarack Advisers's portfolio value rose 42% quarter-over-quarter to $299M.
Based on Tamarack Advisers's 13F filing for Q2 2018, filed 14 Aug 2018.